Effect of quitting smoking on health outcomes during treatment for tuberculosis: secondary analysis of the TB & Tobacco Trial

BackgroundDespite treatment, patients with tuberculosis (TB) who smoke have poorer outcomes compared with non-smokers. It is unknown, however, if quitting smoking during the 6 months of TB treatment improves TB outcomes.MethodsThe TB & Tobacco Trial was a double-blind, placebo-controlled randomi...

Full description

Saved in:
Bibliographic Details
Published inThorax Vol. 77; no. 1; pp. 74 - 78
Main Authors Siddiqi, Kamran, Keding, Ada, Marshall, Anna-Marie, Dogar, Omara, Li, Jinshuo, Huque, Rumana, Fatima, Razia, Khan, Amina, Elsey, Helen, Gabe, Rhian, Kotz, Daniel, Sheikh, Aziz
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and British Thoracic Society 01.01.2022
BMJ Publishing Group LTD
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BackgroundDespite treatment, patients with tuberculosis (TB) who smoke have poorer outcomes compared with non-smokers. It is unknown, however, if quitting smoking during the 6 months of TB treatment improves TB outcomes.MethodsThe TB & Tobacco Trial was a double-blind, placebo-controlled randomised trial of cytisine for smoking cessation in 2472 patients with pulmonary TB in Bangladesh and Pakistan. In a secondary analysis, we investigated the hypothesis that smoking cessation improves health outcomes in patients during the TB treatment course. The outcomes included an eight-point TB clinical score, sputum conversion rates, chest X-ray grades, quality of life (EQ-5D-5L), TB cure plus treatment completion rates and relapse rates. These were compared between those who stopped smoking and those who did not, using regression analysis.ResultsWe analysed the data of 2273 (92%) trial participants. Overall, 25% (577/2273) of participants stopped smoking. Compared with non-quitters, those who quit had better TB cure plus treatment completion rates (91% vs 80%, p<0.001) and lower TB relapse rates (6% vs 14%, p<0.001). Among quitters, a higher sputum conversion rate at week 9 (91% vs 87%, p=0.036), lower mean TB clinical scores (−0.20 points, 95% CI −0.31 to −0.08, p=0.001) and slightly better quality of life (mean EQ-5D-5L 0.86 vs 0.85, p=0.015) at 6 months were also observed. These differences, except quality of life, remained statistically significant after adjusting for baseline values, trial arm and TB treatment adherence rates.ConclusionPatients with TB who stop smoking may have better outcomes than those who don’t. Health professionals should support patients in stopping smoking.
Bibliography:Original research
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0040-6376
1468-3296
1468-3296
DOI:10.1136/thoraxjnl-2020-215926